Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05326165 | NOT YET RECRUITING | Breast Cancer

Early Intervention
Sponsor:

Massachusetts General Hospital

Information provided by (Responsible Party):

Alphonse Taghian

Brief Summary:

This research study is a Pilot Study examining the use of a compression sleeve with embedded sensor to prevent lymphedema.

Condition or disease

Breast Cancer

Breast Cancer Treatment Related Lymphedema

Intervention/treatment

Juzo Compression Sleeve and Glove

Compression Sleeve Sensor

Phase

NA

Detailed Description:

This is a single arm pilot study of a compression sleeve intervention for patients at high risk of breast cancer-related lymphedema (BCRL). The compression sleeve will also include a novel sensor to capture patient adherence to compression wear and pressure applied to the arm. This research is being done because patients receiving lymph node surgery and lymph node radiation for breast cancer are at risk of lymphedema on the arm, trunk or breast/chest wall on the side of treatment. There is some evidence that compression sleeves may prevent progression of early swelling to lymphedema. This study is looking to determine if: 1. a compression garment worn for four weeks helps to prevent breast cancer-related lymphedema (BCRL) in those at high risk of BCRL 2. a sensor attached to the sleeve is accurately measuring time worn and pressure applied 3. participants are wearing the compression for the prescribed time, and if not, what are the barriers to wear 4. participants adhere to the study schedule for filling out patient surveys regarding symptoms and satisfaction with screening. Findings from this study will apply to the development of a larger randomized controlled trial to examine if compression prevents progression to BCRL for patients with low volume swelling. Study procedures include screening for eligibility, treatment including evaluations and follow up visits. Study treatment will last for four weeks with follow up at one, three, six, nine and 12 months. It is expected that about 40 people will take part in this research study. This study is receiving financial support from the Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema (AG Taghian); the Olayan-Xefos Family Fund for Breast Cancer Research (AG Taghian), and the Heinz Family Foundation (AGTaghian). Juzo Inc. is supporting this research study by providing compression garments and a Juzo pressure monitor. Impedimed Inc is supporting this study by providing a Sozo bioimpedance measurement device for research use.

Study Type : INTERVENTIONAL
Estimated Enrollment : 40 participants
Masking : NONE
Primary Purpose : SUPPORTIVE_CARE
Official Title : Preventing the Progression of Low Volume Swelling to Breast Cancer-related Lymphedema: a Pilot Study
Actual Study Start Date : 2025-05
Estimated Primary Completion Date : 2026-06-30
Estimated Study Completion Date : 2026-06-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Eligible participants will be female, \>/= 18 years, who underwent BC surgery for invasive or in-situ carcinoma with unilateral axillary lymph node dissection (ALND) (with or without contralateral prophylactic SLNB). Because of the extremely low incidence of BC in children and males, only female participants over the age of 18 will be included.
  • * Eligible participants will demonstrate low volume swelling (RVC 5-\<10%) \>/=12 weeks postoperatively
  • * Eligible participants will read and comprehend English, with the ability to understand and the willingness to sign a written consent document.
  • * Most patients treated for breast cancer will have undergone SLNB for axillary staging, and are therefore at lower risk for BCRL, compared to patients with ALND and/or regional lymph node radiation (RLNR). We have chosen to include only patients at high risk of BCRL, i.e., those who have undergone ALND, and we will not be including those who are at low BCRL risk, i.e., had only SLNB for axillary staging on the side of BC.
Exclusion Criteria
  • * Participants who have bilateral BC (ie. contralateral staging SLNB or ALND) will not be eligible due to the need of a contralateral control arm for the RVC equation.
  • * Participants will not be eligible if they have been diagnosed and/or treated for BCRL.
  • * Participants will not be eligible if they have metastases that may cause BCRL. Participants with metastatic disease will be excluded.
  • * Participants with implanted cardiac devices and those who are pregnant will be excluded from the Sozo measurement component of the study.
Early Intervention

Location Details

NCT05326165

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Massachusetts

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States, 02114